The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis - 30/11/22

Joyce M.C. Teng, MD, PhD ^a, Christopher G. Bunick, MD, PhD ^{b, ⁎} , Scott Guenthner, MD ^{c, d}, Dedee F. Murrell, MD ^e, Kalyani Marathe, MD, MPH ^f, Steven Kempers, MD ^g, Kimmie Eads, MSN ^d, Alan M. Mendelsohn, MD ^h, Jessica Raiz, MPH ^h, Amir Tavakkol, PhD ^h, Leslie Castelo-Soccio, MD, PhD ⁱ

^a Department of Dermatology, School of Medicine, Stanford University, Palo Alto, California 

^b Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 

^c The Dermatology Center of Indiana, Plainfield, Indiana 

^d The Indiana Clinical Trials Center, PC, Plainfield, Indiana 

^e Department of Dermatology, University of New South Wales, School of Medicine, Sydney, New South Wales, Australia 

^f Division of Dermatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 

^g Associated Skin Care Specialists, New Brighton, Minnesota 

^h Timber Pharmaceuticals, Basking Ridge, New Jersey 

ⁱ Division of Pediartics and Dermatology, University of Pennsylvania, Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 

^∗Correspondence to: Christopher G. Bunick, MD, PhD, Associate Professor of Dermatology, Yale Department of Dermatology, 333 Cedar St, LCI 501, PO Box 208059, New Haven, CT 06520-8059Yale Department of Dermatology333 Cedar St, LCI 501, PO Box 208059New HavenCT06520-8059